lifestyle.longislandreport.org

Author: RIGEL PHARMACEUTICALS, INC.

Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology

March 31, 2026
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update

February 24, 2026
Rigel Appoints Michael P. Miller to the Board of Directors

February 3, 2026
Rigel Provides Business Update and 2026 Outlook

January 12, 2026
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

January 9, 2026
Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 7, 2026
Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition

December 7, 2025
Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference

November 27, 2025
Rigel to Present at the Jefferies Global Healthcare Conference in London

November 14, 2025
Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update

November 7, 2025